Aclidinium bromide for exercise endurance in stable moderate to severe COPD

Phase 3, randomised, double-blind trial of aclidinium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Almirall. Primary endpoint: Change from baseline in endurance time during constant work rate cycle ergometry to symptom limitation at 75% of Wmax after 3 weeks of treatment. Started Aug 2011; status: completed.